Targeted immune interventions for an HIV-1 cure

M Perreau, R Banga, G Pantaleo - Trends in molecular medicine, 2017 - cell.com
M Perreau, R Banga, G Pantaleo
Trends in molecular medicine, 2017cell.com
Combination antiretroviral therapy (cART) induces durable suppression of virus replication
but is unable to eradicate HIV. Invariably, virus rebound follows treatment interruption and
life-long cART is thus required. Advances have been made in our understanding of HIV
latency, identification of HIV cell reservoirs, regulation of HIV-specific immune responses, as
well as in the development of broad neutralizing antibodies and putative therapeutic
vaccines. These have provided a scientific basis to explore alternative strategies that …
Combination antiretroviral therapy (cART) induces durable suppression of virus replication but is unable to eradicate HIV. Invariably, virus rebound follows treatment interruption and life-long cART is thus required. Advances have been made in our understanding of HIV latency, identification of HIV cell reservoirs, regulation of HIV-specific immune responses, as well as in the development of broad neutralizing antibodies and putative therapeutic vaccines. These have provided a scientific basis to explore alternative strategies that achieve durable suppression of viremia in the absence of cART, the so-called functional cure. Single intervention strategies have shown promise, albeit with limited efficacy. Consequently, a combination of interventions aiming to stimulate the immune response and prevent new rounds of viral infection and spreading may render the HIV functional cure a feasible goal.
cell.com